Description: Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
Home Page: renovarobio.com
2080 Century Park East
Los Angeles,
CA
90067
United States
Phone:
(305) 918-1980
Officers
| Name | Title |
|---|---|
| Mr. Simon Tarsh | Interim Chief Financial Officer |
| Dr. Francois Binette M.Sc., Ph.D. | COO and Executive VP for Research & Development |
| Mr. David H. Weinstein | CEO & Director |
| Dr. Serhat Gümrükcü | Co-Founder & Inventor |
| Mr. Greg Duczynski Ph.D. | Senior Vice President for Clinical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2678 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 25 |